
 [
{
"symbol" : "524816",
"exchange" : "BOM",
"id": "703996",
"t" : "524816",
"e" : "BOM",
"name" : "Natco Pharma Ltd."
, "f_reuters_url" : "http:\u002F\u002Fstocks.us.reuters.com\u002Fstocks\u002Fratios.asp?rpc=66\u0026symbol=",
"f_recent_quarter_date" : "",
"f_annual_date" : "",
"f_ttm_date" : "",
"financials" :
[{
"f_type" : "Income\u0026nbsp\u003BStatement"
,"url" : "http:www.google.comfinance?fstype=ii&q=BOM:524816"
,"f_figures" :
[
]
},
{
"f_type" : "Balance\u0026nbsp\u003BSheet"
,"url" : "http:www.google.comfinance?fstype=bi&q=BOM:524816"
,"f_figures" :
[
]
},
{
"f_type" : "Cash\u0026nbsp\u003BFlow"
,"url" : "http:www.google.comfinance?fstype=ci&q=BOM:524816"
,"f_figures" :
[
]
}],
"kr_recent_quarter_date" : "Q4 (Dec \u002717)",
"kr_annual_date" : "2017",
"kr_ttm_date" : "TTM",
"keyratios" :
[
{
"title" : "Net profit margin",
"recent_quarter" : "38.67%",
"annual" : "23.48%",
"ttm" : "28.42%"
},
{
"title" : "Operating margin",
"recent_quarter" : "47.90%",
"annual" : "30.47%",
"ttm" : "36.01%"
},
{
"title" : "EBITD margin",
"recent_quarter" : "",
"annual" : "33.22%",
"ttm" : "39.08%"
},
{
"title" : "Return on average assets",
"recent_quarter" : "",
"annual" : "23.43%",
"ttm" : ""
},
{
"title" : "Return on average equity",
"recent_quarter" : "",
"annual" : "33.01%",
"ttm" : ""
},
{
"title" : "Employees",
"recent_quarter" : "4,411",
"annual" : "-",
"ttm" : "-"
}
]
, "c" : "-3.35",
"l" : "775.05",
"cp" : "-0.43",
"ccol" : "chr",
"op" : "780.00",
"hi" : "785.00",
"lo" : "768.90",
"vo" : "42,475.00",
"avvo" : "",
"hi52" : "1,080.00",
"lo52" : "671.25",
"mc" : "143.02B",
"pe" : "23.62",
"fwpe" : "",
"beta" : "",
"eps" : "32.81",
"dy" : "1.06",
"ldiv" : "7.00",
"shares" : "184.49M",
"instown" : "",
"eo":""
, "related" : [
{
"id" : "703996",
"name" : "Natco Pharma Ltd.",
"t" : "524816",
"e" : "BOM",
"l" : "775.05",
"c" : "-3.35",
"mc" : "143.02B",
"cp" : "-0.43",
"ccol" : "chr"
}
,
{
"id" : "16302121",
"name" : "Fresenius Kabi Oncology Ltd",
"t" : "FKONCO",
"e" : "NSE",
"l" : "132.45",
"c" : "-0.05",
"mc" : "20.96B",
"cp" : "-0.04",
"ccol" : "chr"
}
,
{
"id" : "4349663",
"name" : "Everest Organics Ltd",
"t" : "524790",
"e" : "BOM",
"l" : "139.95",
"c" : "+0.20",
"mc" : "1.12B",
"cp" : "0.14",
"ccol" : "chg"
}
,
{
"id" : "4270139",
"name" : "Sun Pharma Advanced Research Company",
"t" : "SPARC",
"e" : "NSE",
"l" : "439.80",
"c" : "-18.20",
"mc" : "111.24B",
"cp" : "-3.97",
"ccol" : "chr"
}
,
{
"id" : "6462769",
"name" : "Torrent Pharmaceuticals Ltd",
"t" : "TORNTPHARM",
"e" : "NSE",
"l" : "1,357.35",
"c" : "+20.80",
"mc" : "227.74B",
"cp" : "1.56",
"ccol" : "chg"
}
,
{
"id" : "2456500",
"name" : "Wanbury Limited",
"t" : "WANBURY",
"e" : "NSE",
"l" : "40.00",
"c" : "+1.00",
"mc" : "928.80M",
"cp" : "2.56",
"ccol" : "chg"
}
,
{
"id" : "679412034444482",
"name" : "Bajaj Healthcare Ltd",
"t" : "539872",
"e" : "BOM",
"l" : "378.75",
"c" : "0.00",
"mc" : "2.61B",
"cp" : "0.00",
"ccol" : "chb"
}
,
{
"id" : "8708343",
"name" : "SMS Pharmaceuticals Ltd",
"t" : "SMSPHARMA",
"e" : "NSE",
"l" : "89.35",
"c" : "+0.60",
"mc" : "7.59B",
"cp" : "0.68",
"ccol" : "chg"
}
,
{
"id" : "7222829",
"name" : "Makers Laboratories Ltd",
"t" : "506919",
"e" : "BOM",
"l" : "81.35",
"c" : "+1.15",
"mc" : "406.07M",
"cp" : "1.43",
"ccol" : "chg"
}
,
{
"id" : "5394531",
"name" : "Neuland Laboratories Ltd.",
"t" : "NEULANDLAB",
"e" : "NSE",
"l" : "707.35",
"c" : "+0.70",
"mc" : "6.28B",
"cp" : "0.10",
"ccol" : "chg"
}
,
{
"id" : "805988453466693",
"name" : "Sakar Healthcare Ltd",
"c" : "",
"mc" : "",
"cp" : "",
"ccol" : ""
}
]
, "summary" : [{
"address": "Natco House, Road No 2, Banjara Hills, HYDERABAD, 500034, India",
"phone": "+91-40-23547532",
"fax": "+91-40-23545298",
"url": "http:\u002F\u002Fwww.natcopharma.co.in\u002F",
"overview" : "Natco Pharma Limited is a pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The Company\u0027s segments include active pharmaceuticals ingredient, finished dosage formulations, job works, pharmacy and others. The Company\u0027s product categories include Domestic Formulations, International Formulations, API\u0027s and Blockbusters. The Company\u0027s products include Alphalan, Bandrone, Bendit, Clokeran, Lenalid, Thioplan, Anastronat, Capnat, Fulvenat, Kabanat, Natdox-LP, Rapact, Temonat, X-Trant, Glatimer, Hepcinat, Natdac, Natzold, Tigi, Alprazolam, Chloroquine Phosphate, Lansoprazole, Letrozole, Granisetron, Rizatriptan IR, Imatinib, Salmeterol Xinafoate, Sertraline Form I, Ibandronate Sodium Monohydrate, Pantoprazole Sodium Sesquihydrate, Ondansetron Hydrochloride (Injectable Grade), Daclatasvir and Glatiramer Acetate. The Company manufactures over 20 products under contract."
} ]
, "management" : [
{
"name" : "V. C. Nannapaneni",
"age" : "68",
"title" : "Executive Chairman of the board, Managing Director"
}
,
{
"name" : "Rajeev Nannapaneni",
"age" : "37",
"title" : "Executive Vice Chairman of the Board, Chief Executive Officer"
}
,
{
"name" : "S. V. V. N. Appa Rao",
"title" : "Chief Financial Officer, Vice President - Finance and Accounts"
}
,
{
"name" : "Linga Rao",
"title" : "President - Technical Affairs, Director"
}
,
{
"name" : "P. S. R. K. Prasad",
"title" : "Executive Vice President - Corporate Engineering Services, Additional Wholetime Director"
}
,
{
"name" : "M. Adinarayana",
"title" : "Compliance Officer, Company Secretary, Vice President - Legal \u0026 Corporate Affairs"
}
,
{
"name" : "Vivek Chhachhi",
"title" : "Additional Director - Nominee of CX Securities Ltd."
}
,
{
"name" : "M. U. R. Naidu",
"title" : "Additional Director"
}
,
{
"name" : "Leela Digumarti",
"title" : "Independent Director"
}
,
{
"name" : "D. G. Prasad",
"title" : "Independent Additional Director"
}
]
,"moreresources" : [
]
}]
